The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component 5 (C5) using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. The initial focus will be on geographic atrophy, an advanced form of age-related macular degeneration that leads to irreversible vision loss.
GM Takes A Leaf Out Of Tesla’s Book: EVs To Double As Home Backup Power Sources During Blackouts
General Motors (NYSE:GM) revealed its intention to outfit all its electric vehicles with the capability to serve as…
